Zosuquidar (LY335979) 3HCl: Potent P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a trihydrochloride salt that acts as a highly selective and potent inhibitor of P-glycoprotein (P-gp), a central ATP-dependent efflux pump that drives multidrug resistance (MDR) in cancer cells (APExBIO). At low micromolar concentrations (0.1 μM), Zosuquidar fully restores sensitivity to chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing tumor cells (biotin-hpdp.com). Clinical and preclinical models show that Zosuquidar enhances antitumor activity without significantly altering the pharmacokinetics of co-administered chemotherapeutics (DOI:10.1016/j.biopha.2025.118665). The compound is soluble in DMSO and requires storage at -20°C for optimal stability. Zosuquidar is not intended for diagnostic or therapeutic use in humans.

Biological Rationale

P-glycoprotein (P-gp, also called ABCB1 or MDR1) is an ATP-binding cassette transporter that actively effluxes structurally diverse drugs from the cytoplasm to the extracellular space. It is highly expressed in tissues such as the brain, liver, intestine, and various tumor types. Overexpression of P-gp is a major mechanism of multidrug resistance (MDR) in cancers, leading to the failure of chemotherapeutic regimens (biotin-hpdp.com). This efflux pump lowers intracellular drug concentrations, rendering standard-of-care agents ineffective. Targeting P-gp is a validated strategy for overcoming MDR, particularly in hematological malignancies like acute myeloid leukemia (AML) and solid tumors including non-Hodgkin's lymphoma (rilmenidinerx.com). Recent pharmacokinetic and transporter studies have shown that modulating P-gp can profoundly impact tissue drug disposition and therapeutic efficacy (DOI:10.1016/j.biopha.2025.118665).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar is a third-generation, non-competitive P-gp inhibitor. It binds to the substrate-binding domain of P-gp and blocks the translocation of cytotoxic drugs out of cancer cells. This action is competitive with drugs such as vinblastine. In vitro, Zosuquidar at 0.1 μM concentration completely reverses resistance to multiple chemotherapeutics in P-gp overexpressing cell lines (APExBIO). Zosuquidar does not significantly inhibit other ATP-binding cassette transporters, including MRP1 or BCRP, at pharmacologically relevant concentrations (rilmenidinerx.com). In vivo, Zosuquidar enhances the efficacy of standard chemotherapies without altering their systemic pharmacokinetics, as shown in murine leukemia and human lung carcinoma xenograft models (DOI:10.1016/j.biopha.2025.118665).

Evidence & Benchmarks

• At 0.1 μM, Zosuquidar reverses resistance to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing leukemia and tumor cell lines (APExBIO).
• In vivo, Zosuquidar increases survival and reduces tumor burden in murine leukemia and human lung carcinoma xenograft models when combined with chemotherapy, with no significant alteration in drug pharmacokinetics (DOI:10.1016/j.biopha.2025.118665).
• Zosuquidar (LY335979) 3HCl demonstrates minimal off-target effects and low toxicity in preclinical and early-stage clinical studies (rilmenidinerx.com).
• Phase I/II clinical trials using Zosuquidar in combination with CHOP or vinorelbine regimens show effective P-gp inhibition and manageable safety profiles in non-Hodgkin’s lymphoma and advanced solid tumors (biotin-hpdp.com).
• Pharmacokinetic variability due to transporter modulation, including P-gp, is a critical determinant of drug disposition, as shown in integrated tissue distribution studies (DOI:10.1016/j.biopha.2025.118665).

This article extends the practical workflows outlined in "Overcoming Multidrug Resistance: Practical Lab Strategies" by providing deeper mechanistic context and clinical translation insights, and clarifies the selectivity profile compared to "Strategic Disruption of P-gp" by focusing on PK/PD nuances and toxicity boundaries.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is widely used for:

• Reversing multidrug resistance (MDR) in cancer cell-based assays.
• Enhancing chemosensitivity in acute myeloid leukemia (AML) and non-Hodgkin’s lymphoma models.
• Translational research on P-glycoprotein-mediated drug transport mechanisms.
• Evaluating drug-drug interactions mediated by ATP-binding cassette transporters.

However, Zosuquidar is not suitable for:

• Direct clinical or diagnostic use in humans (for research use only).
• Inhibition of non-P-gp transporters at standard concentrations.
• Long-term solution storage due to stability considerations (see product documentation).

Common Pitfalls or Misconceptions

• Zosuquidar is not a pan-ABC transporter inhibitor: It does not significantly inhibit MRP1 or BCRP at relevant concentrations.
• Not effective against non-P-gp mediated resistance: Resistance mechanisms unrelated to P-gp, such as those involving altered cell metabolism or DNA repair, are not addressed.
• Storage limits: Zosuquidar solutions degrade over time, especially above -20°C or at repeated freeze-thaw cycles.
• Not for diagnostic/therapeutic use in humans: The compound is intended exclusively for research use.
• Potential for cell line variability: Efficacy may vary depending on P-gp expression levels and cell type.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl, available from APExBIO (SKU A3956), is supplied as a trihydrochloride salt with a molecular weight of 527.6 g/mol (product page). It is soluble in DMSO and should be stored at -20°C. For in vitro assays, a working concentration of 0.1–1 μM is recommended. Preparation should be performed under sterile conditions, and solutions should be freshly made to avoid degradation. For in vivo studies, dosing regimens must be tailored based on animal model and pharmacokinetic parameters. APExBIO provides detailed handling and solubility guidelines to maximize experimental reproducibility.

For expanded protocol design, see "Zosuquidar (LY335979): P-gp Inhibitor for Multidrug Resistance", which offers troubleshooting and benchmarking strategies; this article updates mechanistic insights and clinical translation.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a gold-standard tool for dissecting and overcoming P-glycoprotein-mediated multidrug resistance in cancer research. Its high selectivity, low toxicity, and validated efficacy in restoring drug sensitivity make it indispensable for translational oncology studies. Emerging PK/PD data suggest that careful integration of Zosuquidar into experimental workflows can clarify transporter-mediated drug disposition and resistance mechanisms. Further studies may elucidate its potential in combination regimens and inform next-generation MDR reversal strategies.